Temple Therapeutics is focused on developing innovative therapies and early diagnostic tools aimed at addressing painful diseases that disproportionately affect underserved populations, particularly women. Their pipeline includes a range of first-in-class healthcare technologies that leverage a novel approach to cellular metabolism. Notably, they are working on TTX333 and TTX330, which are designed to inhibit fibrotic tissue growth at surgical sites, as well as a panel of biomarker tests for early detection of endometriosis and ovarian tumors. These advancements aim to improve patient outcomes by enabling earlier treatment and better management of these conditions.

The company emphasizes a patient-centered approach, drawing insights from real-world experiences of patients and medical practitioners to inform their product development. Their mission is to transform lives by creating holistic treatments that not only detect and treat diseases but also promote overall well-being. By addressing disparities in healthcare access and outcomes across various demographics, Temple Therapeutics aims to deliver compassionate care that meets the unique needs of women facing these challenging health issues.

Netherlands

A clinical-stage biotechnology company pioneering a female-focused precision medicine approach using validated biobanks for the discovery, development, and commercialization of novel therapeutics and companion diagnostics in women's health.

Temple Therapeutics

Company Details